Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor and Eptifibatide Regimens in PCI
NCT01919723Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2014
- Primary completion
- Dec 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eptifibatide in acute coronary syndrome (ACS) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Change in Percent Inhibition of Platelet Aggregation at 2 hours. Started Feb 2014; status: completed.
02
Drugs
eptifibatide
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT01919723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01919723.